编号 7 (2016)

Back pain occasionally occurs in most people, and the most common mechanism of its occurrence is an inflammation of muscles and joints and ligaments of the spine. In modern literature, this condition is termed «non-specific back pain» due to the fact that the pathogenesis of this disease is the same regardless of the cause of back pain. However, following the ancient principle of «treat not a disease, but the patient», the individualized approaches to diagnosis and treatment of this non-specific condition can be completely different, forming the basis of modern personalized medicine.

The neuronal damage in ischemic cerebral diseases is associated with series of molecular mechanisms, which can be a target for pharmacological neuroprotective interventions. Currently, there is no consensus about the potentials of neuroprotective therapy in hyperacute ischemic stroke. However, a number of studies had shown the positive effects of citicoline by reducing the severity of residual neurological deficit. In chronic cerebrovascular insufficiency, the effect of therapy on the rate of progression of cognitive disorders can be considered as a criterion of efficiency of neuroprotective therapy. Available evidence allows to discuss neuroprotective effect of antihypertensive and neurometabolic therapy.

In clinical practice, we are often faced with patients who have back pain and joint pain in combination with a variety of comorbid medical conditions (arterial hypertension, coronary artery disease, cerebrovascular disease, chronic obstructive pulmonary disease, liver disease, kidney disease, etc.). Therefore, the issues of frequency of systemic complications of therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) and its potential interaction with drugs receiving by the patient have identified the relevance of this article. Now it is proved that among a number of NSAIDs, the original meloxicam (Movalis) is characterized not only by low-risk for the development of comorbid somatic side effects, but a good safety spectrum in combination therapy, making it possible to use this drug in general medical practice.

The article presents the final results of a prospective, open 12-week study, KORONA study, which was aimed to the evaluation of the efficacy and cardiovascular safety of amtolmetin guacil (AMG) in patients with chronic lower back pain and controlled arterial hypertension. The study included 60 patients aged 18 and older, met with the modified New York criteria for ankylosing spondylitis, with the intensity of back pain of 4.0 and more points according to the numerical rating scale. Patients were divided into 2 groups: the first group (n=41) - patients with controlled arterial hypertension (AH), the second group (n=19) - without arterial hypertension. During first 14 days, patients received AMG at a dose of 180 mg/day, followed by 600 mg/day for 12 weeks. It has been shown that AMG is effective and safe in treating lower back pain in the in the short term. Application of AMG requires monitoring of blood pressure in individuals with high risk of cardiovascular events, especially in the first two weeks of treatment.

The article presents the results of evaluation of the efficacy and safety of adalimumab in 53 children with juvenile idiopathic arthritis without systemic manifestations, as well as the evaluation of the timing and the possibility of reaching of inactive disease, the frequency of exacerbations, as well as their causes and side effects.

The results of application of the drug Chondrogard (chondroitin sulphate) in 200 patients with fractures of various segments of the limbs. The introduction of the drug Chondrogard was carried out intramuscularly in a dose of 1 ml (100 mg) a day (first 3 injections), the fourth and subsequent injection of 2 ml (200 mg) through the day. During the observation period, which was 36 days, all patients had completed 18 injections of the drug. The result of the study revealed Chondrogen clinical efficacy in the treatment of patients with fractures of different localization.

Monitoring and maintaining magnesium homeostasis are important for preserving bone integrity. Most of the population has a substantial nutritional magnesium deficiency, which leads to the onset and worsening of osteoporosis. The article discusses the osteoporosis-associated magnesium deficiency, as well as the need to incorporate magnesium citrate in the combination therapy of the disease.